Uncategorized
Aura Biosciences’ ocular melanoma treatment receives fast track designation
AU-011, an investigational, first-in-class targeted therapy for ocular melanoma treatment, was granted fast track designation by the FDA, according to a press release from Aura Biosciences.In addition, at Wills Eye Hospital, the first patient was enrolled and dosed in a phase 1b trial of the treatment, which is designed to target and selectively destroy cancer cells using viral nanoparticle conjugates.